Brand Erosion Post-Patent Expiry – An analysis of small molecule brand erosion post-patent expiry

Introduction

Pharma is facing slowing sales growth in the developed pharmaceutical markets, driven by increasing generic competition. However, the speed and severity of brand erosion is by no means equal across countries, prescribing setting, therapy area and formulation type; factors which are of key importance when managing and forecasting branded drug sales.
Features and benefits

* Analyzes brand erosion (in terms of volume and value) in the US, Japan, France, Germany, Italy, Spain, UK, Australia China and Russia* Assesses brand erosion across the two major prescribing settings (retail and hospital)* Examines brand erosion across the various different therapy areas* Analyzes brand erosion according to drug formulation (oral, oral long lasting, parenteral and other formulation types)
Highlights

Brands tended not to experience generic erosion in China following patent expiry since they often face generic competition from the outset, and instead continue to grow both in terms of volume and value.Brand erosion was greater in terms of speed and severity in the hospital setting most likely reflecting the greater brand loyalty among patients in the retail setting.In terms of erosion by therapy areas, sales and volume erosion was the greatest among infectious disease, oncology, and cardiovascular small molecule brands.
Your key questions answered

* Evaluate the evolving prescription pharmaceutical landscape and how this is being impacted by generics* Quantify sales and volume erosion across 10 major pharmaceutical markets according to prescribing setting, therapy areas, and drug formulation* Assess drivers and resistors for the uptake of generic drugs in each market
[Studien Infos ausblenden]

Executive Summary
Introduction
Strategic scoping and focus
Key Findings
Brand erosion by country
Brand erosion by prescribing setting (retail versus hospital)
Brand erosion by therapy area
Brand erosion by formulation
Overview of drugs analyzed
Related reports
2. OVERVIEW – SMALL MOLECULE BRAND EROSION
Overview – overview of drugs analyzed
Overview – mean level of brand erosion across the world’s major markets
Overview – generics market dynamics
Generics volume uptake
Generics value uptake
Generics market size
Overview – generics drivers and resistors
US – Generics drivers and resistors
Japan – Generics drivers and resistors
France – Generics drivers and resistors
Germany – Generics drivers and resistors
Italy – Generics drivers and resistors
Spain – Generics drivers and resistors
UK – Generics drivers and resistors
China – Generics drivers and resistors
Brazil – Generics drivers and resistors
India – Generics drivers and resistors
Russia – Generics drivers and resistors
Australia – Generics drivers and resistors
Overview – brand erosion in the retail and hospital setting
Retail and hospital erosion by country
Overview – brand erosion by therapy area
Brand erosion by therapy area – Infectious diseases
Brand erosion by therapy area – Cardiovascular
Brand erosion by therapy area – Oncology
Brand erosion by therapy area – Central Nervous System
Brand erosion by therapy area – Respiratory
Brand erosion by therapy area – Metabolic disorders
Brand erosion by therapy area – Immunology and inflammation
Brand erosion by therapy area – Other
Overview – brand erosion by drug formulation
Brand erosion by drug formulation – Oral normal
Brand erosion by drug formulation – Oral long lasting
Brand erosion by drug formulation – Parenteral
Brand erosion by drug formulation – Other
3. US – SMALL MOLECULE BRAND EROSION
US – overview of drugs analyzed
US – mean level of brand erosion
US – brand erosion in the retail and hospital setting
US – brand erosion by therapy area
US – brand erosion by drug formulation
4. JAPAN – SMALL MOLECULE BRAND EROSION
Japan – overview of drugs analyzed
Japan – mean level of brand erosion
Japan – brand erosion in the retail and hospital setting
Japan – brand erosion by therapy area
Japan – brand erosion by drug formulation
5. FRANCE – SMALL MOLECULE BRAND EROSION
France – overview of drugs analyzed
France – mean level of brand erosion
France – brand erosion in the retail and hospital setting
France – brand erosion by therapy area
France – brand erosion by drug formulation
6. GERMANY – SMALL MOLECULE BRAND EROSION
Germany – overview of drugs analyzed
Germany – mean level of brand erosion
Germany – brand erosion in the retail and hospital setting
Germany – brand erosion by therapy area
Germany – brand erosion by drug formulation
7. ITALY – SMALL MOLECULE BRAND EROSION
Italy – overview of drugs analyzed
Italy – mean level of brand erosion
Italy – brand erosion in the retail and hospital setting
Italy – brand erosion by therapy area
Italy – brand erosion by drug formulation
8. SPAIN – SMALL MOLECULE BRAND EROSION
Spain – overview of drugs analyzed
Spain – mean level of brand erosion
Spain – brand erosion in the retail and hospital setting
Spain – brand erosion by therapy area
Spain – brand erosion by drug formulation
9. UK – SMALL MOLECULE BRAND EROSION
UK – overview of drugs analyzed
UK – mean level of brand erosion
UK – brand erosion in the retail and hospital setting
UK – brand erosion by therapy area
UK – brand erosion by drug formulation
10. AUSTRALIA – SMALL MOLECULE BRAND EROSION
Australia – overview of drugs analyzed
Australia – mean level of brand erosion
Australia – brand erosion in the retail and hospital setting
Australia – brand erosion by therapy area
Australia – brand erosion by drug formulation
11. RUSSIA – SMALL MOLECULE BRAND EROSION
Russia – overview of drugs analyzed
Russia – mean level of brand erosion
Russia – brand erosion in the retail and hospital setting
Russia – brand erosion by therapy area
Russia – brand erosion by drug formulation
12. CHINA – SMALL MOLECULE BRAND EROSION
China – overview of brand erosion
13. BIBLIOGRAPHY
Overview – small molecule brand erosion
Publications and online articles
Datamonitor reports and products
US – small molecule brand erosion
Publications and online articles
Japan – small molecule brand erosion
Publications and online articles
Datamonitor reports and products
France – small molecule brand erosion
Publications and online articles
Germany – small molecule brand erosion
Publications and online articles
Italy – small molecule brand erosion
Publications and online articles
Spain – small molecule brand erosion
Publications and online articles
UK – small molecule brand erosion
Publications and online articles
Datamonitor reports and products
Australia – small molecule brand erosion
Publications and online articles
Datamonitor reports and products
Russia – small molecule brand erosion
Publications and online articles
China – small molecule brand erosion
Publications and online articles
APPENDIX
Exchange rates used in this report
US brand erosion – additional data and analysis
Japan brand erosion – additional data and analysis
France brand erosion – additional data and analysis
Germany brand erosion – additional data and analysis
Italy brand erosion – additional data and analysis
Spain brand erosion – additional data and analysis
UK brand erosion – additional data and analysis
Australia brand erosion – additional data
Russia brand erosion – additional data and analysis
Brand erosion – methodology
Datamonitor prescription pharmaceutical definition and therapy area classification

[Inhaltsverzeichnis ausblenden]